Home > Insider Trading > Filing (0001209191-11-017181)

Filing Details

Accession Number:: 0001209191-11-017181
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2011-03-10 12:00:00
Reporting Period:: 2011-03-08

Filing Date:: 2011-03-10
Accepted Time:: 2011-03-10 17:47:38
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1333170	Nxstage Medical Inc.	NXTM	Electromedical & Electrotherapeutic Apparatus (3845)	043454702

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1341405	L Winifred Swan	C/O Nxstage Medical, Inc. 439 South Union Street, 5Th Floor Lawrence MA 01843	Svp And General Counsel	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2011-03-08	5,000	$21.91	50,340	No	4	S	Direct
Common Stock	Acquisiton	2011-03-08	6,795	$0.00	57,135	No	4	A	Direct
Common Stock	Acquisiton	2011-03-08	11,982	$0.00	69,117	No	4	M	Direct
Common Stock	Disposition	2011-03-08	5,963	$21.89	63,154	No	4	F	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	A	Direct
No	4	M	Direct
No	4	F	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Unit	Acquisiton	2011-03-08	35,945	$0.00	35,945	$0.00
Common Stock	Restricted Stock Unit	Disposition	2011-03-08	11,982	$0.00	11,982	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
35,945			No	4	A	Direct
23,963			No	4	M	Direct

Footnotes

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2010, amended August 23, 2010 and further amended on December 16, 2010.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.66 to $22.08. The reporting person undertakes to provide to the issuer, any holder of the issuer's stock, or the SEC, upon request, full information regarding the number of shares sold at each separate price within the range described above.
In March 2010, the Compensation Committee of the Board of Directors (the "Compensation Committee") established the NxStage Medical, Inc. (the "Company") 2010 Corporate Bonus Plan with the amount of awards to be determined based upon the satisfaction of 2010 revenue and cash consumption targets. On March 8, 2011, the Compensation Committee awarded the reporting person 6,795 shares of common stock based on its evaluation of the achievement of performance criteria established under the 2010 Corporate Bonus Plan.
Shares of common stock acquired upon the vesting of restricted stock units.
This transaction reflects the withholding of shares of the Company's common stock to satisfy the reporting person's tax liability incurred in connection with the restricted stock units (the "Award") granted to the reporting person on March 8, 2011 pursuant to the Company's 2010 Corporate Bonus Plan and the vesting of the first tranche of the Award on March 8, 2011 pursuant to the Company's 2010 Performance Share Plan.
Each restricted stock unit represents a contingent right to receive one share of the Company's common stock
In March 2010, the Compensation Committee established the Company's 2010 Performance Share Plan with the amount of awards to be determined based upon the satisfaction of 2010 revenue and cash consumption targets. On March 8, 2011, the Compensation Committee granted the reporting person 35,945 restricted stock units based on its evaluation of the achievement of performance criteria under the Company's 2010 Performance Share Plan. The award vested 33 1/3rd% on the date of grant (March 8, 2011), with the balance vesting in two equal installments on December 31, 2011 and December 31, 2012.